What do systematic reviews say?

Summary of findings table ‐ Cannabis vs placebo

Summary of findings table ‐ Cannabis showed no clear difference in SAEs: number of participants with SAEs ( compared with placebo (low certainty).

• Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis 2022 · Cochrane Headline outcomes only
  OR 1.38 [0.96, 1.99]
  20 studies · 3124 participants
  Low

Summary of findings table ‐ Cannabis vs placebo

Summary of findings table ‐ Cannabis may leads to higher specific AEs:number of participants reporting nervous system… compared with placebo (low certainty).

• Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis 2022 · Cochrane Headline outcomes only
  OR 2.61 [1.53, 4.44]
  7 studies · 1154 participants
  Low

Summary of findings table ‐ Cannabis vs placebo

Summary of findings table ‐ Cannabis may leads to higher specific AEs: number of participants reporting psychiatric disorders ( compared with placebo (low certainty).

• Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis 2022 · Cochrane Headline outcomes only
  OR 1.94 [1.31, 2.88]
  6 studies · 1122 participants
  Low

Summary of findings table ‐ Cannabis vs placebo

It is very uncertain whether summary of findings table ‐ Cannabis changes specific AEs: number of participants reporting drug tolerance ( compared with placebo (very low certainty).

• Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis 2022 · Cochrane Headline outcomes only
  OR 3.07 [0.12, 75.95]
  2 studies · 458 participants
  Very low

Intervention not reported

• Contrast‐enhanced ultrasound for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease 2022 · Cochrane Headline outcomes only
  no estimate extracted
  23 studies · 6546 participants
  Very low

Intervention not reported

• Contrast‐enhanced ultrasound for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease 2022 · Cochrane Headline outcomes only
  no estimate extracted
  13 studies · 1257 participants
  Low

Intervention not reported

• Magnetic resonance imaging for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease 2022 · Cochrane Headline outcomes only
  no estimate extracted
  34 studies · 4841 participants
  Low

Intervention not reported

• Magnetic resonance imaging for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease 2022 · Cochrane Headline outcomes only
  no estimate extracted
  16 studies · 2150 participants
  Low

Intervention not reported

The review found no eligible studies for this question.

• Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

• Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 327 participants
  Moderate

Intervention not reported

The review found no eligible studies for this question.

• Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The review found no eligible studies for this question.

• Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

• Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 167 participants
  Very low

Intervention not reported

• Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 167 participants
  Very low

Intervention not reported

• Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 267 participants
  Very low

Intervention not reported

• Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 799 participants
  Very low

Intervention not reported

• Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 267 participants
  Very low

Intervention not reported

The review found no eligible studies for this question.

• Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

• Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 65 participants
  Low

Intervention not reported

• Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 65 participants
  Low